Your browser doesn't support javascript.
loading
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.
Rodríguez, Francisco; Caruana, Pablo; De la Fuente, Noa; Español, Pía; Gámez, María; Balart, Josep; Llurba, Elisa; Rovira, Ramón; Ruiz, Raúl; Martín-Lorente, Cristina; Corchero, José Luis; Céspedes, María Virtudes.
Afiliação
  • Rodríguez F; Grup d'Oncologia Ginecològica i Peritoneal, Institut d'Investigacions Biomédiques Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Caruana P; Grup d'Oncologia Ginecològica i Peritoneal, Institut d'Investigacions Biomédiques Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • De la Fuente N; Servicio de Cirugía General y del Aparato Digestivo, Hospital HM Rosaleda, 15701 Santiago de Compostela, Spain.
  • Español P; Department of Obstetrics and Gynecology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
  • Gámez M; Department of Pharmacy, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Balart J; Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Llurba E; Department of Obstetrics and Gynecology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
  • Rovira R; Department of Obstetrics and Gynecology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
  • Ruiz R; Grup d'Oncologia Ginecològica i Peritoneal, Institut d'Investigacions Biomédiques Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Martín-Lorente C; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Corchero JL; Institut de Biotecnologia i de Biomedicina and CIBER-BBN, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
  • Céspedes MV; Grup d'Oncologia Ginecològica i Peritoneal, Institut d'Investigacions Biomédiques Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Biomolecules ; 12(6)2022 06 04.
Article em En | MEDLINE | ID: mdl-35740909
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Biomolecules Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Biomolecules Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha